Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
F 0.32 5.81% 0.02
FGEN closed up 5.81 percent on Friday, November 1, 2024, on 70 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 4
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Low Weakness 5.81%
Wide Bands Range Expansion 5.81%
Oversold Stochastic Weakness 5.81%
Stochastic Buy Signal Bullish 0.35%
Wide Bands Range Expansion 0.35%
Oversold Stochastic Weakness 0.35%
NR7 Range Contraction 4.15%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 19 hours ago
Rose Above Previous Day's High about 20 hours ago
Rose Above 10 DMA about 20 hours ago
Up 10% about 20 hours ago
Up 1 ATR about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

FibroGen, Inc Description

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Chronic Kidney Disease Blindness Cornea Collagen Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors

Is FGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.93
52 Week Low 0.29
Average Volume 1,091,843
200-Day Moving Average 1.10
50-Day Moving Average 0.37
20-Day Moving Average 0.34
10-Day Moving Average 0.32
Average True Range 0.03
RSI (14) 41.52
ADX 21.36
+DI 16.33
-DI 23.58
Chandelier Exit (Long, 3 ATRs) 0.31
Chandelier Exit (Short, 3 ATRs) 0.39
Upper Bollinger Bands 0.40
Lower Bollinger Band 0.28
Percent B (%b) 0.33
BandWidth 33.57
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram -0.0008
Fundamentals Value
Market Cap 31.36 Million
Num Shares 98.3 Million
EPS -3.06
Price-to-Earnings (P/E) Ratio -0.10
Price-to-Sales 1.71
Price-to-Book 53.83
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.37
Resistance 3 (R3) 0.37 0.35 0.36
Resistance 2 (R2) 0.35 0.34 0.35 0.36
Resistance 1 (R1) 0.34 0.33 0.34 0.34 0.36
Pivot Point 0.32 0.32 0.32 0.32 0.32
Support 1 (S1) 0.30 0.31 0.31 0.30 0.28
Support 2 (S2) 0.28 0.30 0.28 0.28
Support 3 (S3) 0.27 0.28 0.28
Support 4 (S4) 0.27